Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.

Li CM, Lu Y, Chen J, Costello TA, Narayanan R, Dalton MN, Snyder LM, Ahn S, Li W, Miller DD, Dalton JT.

Pharm Res. 2012 Nov;29(11):3053-63. doi: 10.1007/s11095-012-0814-5. Epub 2012 Jul 4.

2.

A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.

Ahn S, Hwang DJ, Barrett CM, Yang J, Duke CB 3rd, Miller DD, Dalton JT.

Cancer Chemother Pharmacol. 2011 Feb;67(2):293-304. doi: 10.1007/s00280-010-1319-8. Epub 2010 Apr 11.

PMID:
20383708
3.

Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.

Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3459-69.

4.

Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.

Li CM, Chen J, Lu Y, Narayanan R, Parke DN, Li W, Ahn S, Miller DD, Dalton JT.

Drug Metab Dispos. 2011 Oct;39(10):1833-9. doi: 10.1124/dmd.110.036616. Epub 2011 Jul 8.

5.

A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.

Cai P, Lu P, Sharom FJ, Fang WS.

Cancer Lett. 2013 Dec 1;341(2):214-23. doi: 10.1016/j.canlet.2013.08.010. Epub 2013 Aug 11.

PMID:
23941826
6.

2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.

Beckers T, Reissmann T, Schmidt M, Burger AM, Fiebig HH, Vanhoefer U, Pongratz H, Hufsky H, Hockemeyer J, Frieser M, Mahboobi S.

Cancer Res. 2002 Jun 1;62(11):3113-9.

7.

MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.

Sampath D, Discafani CM, Loganzo F, Beyer C, Liu H, Tan X, Musto S, Annable T, Gallagher P, Rios C, Greenberger LM.

Mol Cancer Ther. 2003 Sep;2(9):873-84.

8.
9.

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.

Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R.

Cancer Chemother Pharmacol. 2009 Jan;63(2):201-12. doi: 10.1007/s00280-008-0727-5. Epub 2008 Mar 19.

PMID:
18350296
10.

BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.

Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY.

Cancer Res. 2004 Jul 1;64(13):4621-8.

11.

I-387, a novel antimitotic indole, displays a potent in vitro and in vivo antitumor activity with less neurotoxicity.

Ahn S, Duke CB 3rd, Barrett CM, Hwang DJ, Li CM, Miller DD, Dalton JT.

Mol Cancer Ther. 2010 Nov;9(11):2859-68. doi: 10.1158/1535-7163.MCT-10-0399. Epub 2010 Sep 9.

12.

Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.

Reddy MV, Mallireddigari MR, Pallela VR, Cosenza SC, Billa VK, Akula B, Subbaiah DR, Bharathi EV, Padgaonkar A, Lv H, Gallo JM, Reddy EP.

J Med Chem. 2013 Jul 11;56(13):5562-86. doi: 10.1021/jm400575x. Epub 2013 Jun 25.

13.

Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities.

Liu Z, Zhou Z, Tian W, Fan X, Xue D, Yu L, Yu Q, Long YQ.

ChemMedChem. 2012 Apr;7(4):680-93. doi: 10.1002/cmdc.201100529. Epub 2012 Feb 6.

PMID:
22311585
14.

Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent.

Shetty RS, Lee Y, Liu B, Husain A, Joseph RW, Lu Y, Nelson D, Mihelcic J, Chao W, Moffett KK, Schumacher A, Flubacher D, Stojanovic A, Bukhtiyarova M, Williams K, Lee KJ, Ochman AR, Saporito MS, Moore WR, Flynn GA, Dorsey BD, Springman EB, Fujimoto T, Kelly MJ.

J Med Chem. 2011 Jan 13;54(1):179-200. doi: 10.1021/jm100659v. Epub 2010 Dec 2.

PMID:
21126027
15.

CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo.

Burns CJ, Fantino E, Phillips ID, Su S, Harte MF, Bukczynska PE, Frazzetto M, Joffe M, Kruszelnicki I, Wang B, Wang Y, Wilson N, Dilley RJ, Wan SS, Charman SA, Shackleford DM, Fida R, Malcontenti-Wilson C, Wilks AF.

Mol Cancer Ther. 2009 Nov;8(11):3036-45. doi: 10.1158/1535-7163.MCT-09-0076. Epub 2009 Nov 3.

16.

Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.

Chen J, Wang Z, Li CM, Lu Y, Vaddady PK, Meibohm B, Dalton JT, Miller DD, Li W.

J Med Chem. 2010 Oct 28;53(20):7414-27. doi: 10.1021/jm100884b.

17.

An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.

Colley HE, Muthana M, Danson SJ, Jackson LV, Brett ML, Harrison J, Coole SF, Mason DP, Jennings LR, Wong M, Tulasi V, Norman D, Lockey PM, Williams L, Dossetter AG, Griffen EJ, Thompson MJ.

J Med Chem. 2015 Dec 10;58(23):9309-33. doi: 10.1021/acs.jmedchem.5b01312. Epub 2015 Dec 1.

PMID:
26580420
18.

Formulation and characterization of polyester/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent.

Mundra V, Lu Y, Danquah M, Li W, Miller DD, Mahato RI.

Pharm Res. 2012 Nov;29(11):3064-74. doi: 10.1007/s11095-012-0881-7. Epub 2012 Sep 28.

19.

Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis.

Wang Z, Chen J, Wang J, Ahn S, Li CM, Lu Y, Loveless VS, Dalton JT, Miller DD, Li W.

Pharm Res. 2012 Nov;29(11):3040-52. doi: 10.1007/s11095-012-0726-4. Epub 2012 Mar 13.

20.

Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.

Zhu C, Zuo Y, Wang R, Liang B, Yue X, Wen G, Shang N, Huang L, Chen Y, Du J, Bu X.

J Med Chem. 2014 Aug 14;57(15):6364-82. doi: 10.1021/jm500024v. Epub 2014 Jul 25.

PMID:
25061803

Supplemental Content

Support Center